Moreover, among 152 patients with tumor stage T1, T2, and T3, the DFS rate in those displaying EZH2 gene upregulation was 39.8%, as compared with 55.6 % in those displaying EZH2 downregulation (log-rank test, p = 0.009) (Figure 2D). Here, EZH2 is linked to neoplasm.